Medical researcher in a lab reviewing a bladder tumor cross-section and molecular immunotherapy data on dual screens.
Image Credit: Scientific Frontline / AI generated
Scientific Frontline: Extended "At a Glance" Summary: Muscle-Invasive Bladder Cancer Immunotherapy
The Core Concept: A novel therapeutic approach combines the immunotherapy drug durvalumab and the targeted antibody-drug conjugate enfortumab vedotin before bladder removal surgery, followed by post-surgical immunotherapy alone. This regimen is specifically designed to treat muscle-invasive bladder cancer in patients who cannot tolerate standard cisplatin-based chemotherapy.
Key Distinction/Mechanism: Unlike traditional chemotherapy, this combination attacks cancer through two distinct pathways. Enfortumab vedotin binds to the nectin-4 protein on bladder cancer cells to deliver a localized cytotoxic drug, while durvalumab blocks the PD-L1 protein to prevent tumors from evading the body's immune system. Crucially, the targeted drug is administered only before surgery, sparing patients from its toxicity during post-operative recovery.
Major Frameworks/Components:
- Neoadjuvant therapeutic protocols (pre-surgical tumor reduction).
- Antibody-drug conjugates (ADCs) for targeted cytotoxic delivery.
- Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway.
- Platinum-ineligible oncology pathways for vulnerable patient populations.
Branches of Science: Urologic Oncology, Immunopharmacology, Molecular Oncology, and Surgical Oncology.
Future Application: This protocol establishes a new standard of care for pre-surgical intervention in aggressive, localized cancers, offering a framework to reduce post-operative pharmacological burdens while maintaining high recurrence-free survival rates.
Why It Matters: Nearly half of all patients with muscle-invasive bladder cancer are ineligible for standard chemotherapy due to conditions like kidney dysfunction or nerve damage, historically forcing them directly to surgery with high recurrence risks. This dual-drug combination reduces the risk of death by 42% and lowers the risk of cancer progression or recurrence by 49%, fundamentally improving long-term survival prospects.
A novel therapeutic regimen improves overall survival and reduces the risk of disease recurrence and progression in patients with muscle-invasive bladder cancer, particularly those who cannot receive standard chemotherapy, according to findings from a large international clinical trial co-led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center.
The study, published in The New England Journal of Medicine, found that patients who received a combination of the immunotherapy drug durvalumab and the targeted cancer drug enfortumab vedotin before radical cystectomy, followed by immunotherapy after surgery, had a 42% lower risk of death compared with patients who underwent surgery alone. The treatment also reduced the risk of cancer returning, progressing, or other cancer-related events, including death, by 49%.
The findings establish a novel therapeutic protocol for patients who are unable to receive cisplatin-based chemotherapy, a standard treatment commonly given before radical cystectomy to help reduce the risk of cancer returning.
"Nearly half of patients with muscle-invasive bladder cancer are unable to receive standard cisplatin-based chemotherapy, leaving them with limited treatment options," said Dr. Alexandra Drakaki, professor of medicine and urology at the David Geffen School of Medicine at UCLA and senior author of the study. "These findings give us an opportunity to offer these patients an effective treatment before surgery, with the goal of improving their chances of long-term survival."
Muscle-invasive bladder cancer is an aggressive form of the disease that has grown into the muscular wall of the bladder. Treatment typically involves radical cystectomy, often preceded by chemotherapy to shrink the cancer and reduce the risk of recurrence.
However, many patients cannot receive cisplatin-based chemotherapy due to renal impairment, hearing loss, neuropathy, or other comorbidities. Historically, these patients often proceeded directly to surgery without receiving preoperative systemic therapy, putting them at greater risk of their cancer returning or spreading.
Recent advances in immunotherapy and targeted cancer treatments have begun to expand options for these patients. This research builds on that progress by testing whether combining immunotherapy with enfortumab vedotin, a type of targeted treatment known as an antibody-drug conjugate, could improve outcomes when given before surgery.
Enfortumab vedotin works by attaching to a protein called nectin-4, found on many bladder cancer cells, and delivering a targeted cytotoxic payload directly to those cells. Conversely, durvalumab enables the immune system to recognize and target malignant cells by blocking a protein called PD-L1 that tumors can use to evade immune detection.
By combining these approaches, researchers hoped to attack cancer cells directly while also strengthening the immune system's ability to fight the disease.
To evaluate whether this approach could improve outcomes, investigators conducted a large international phase 3 clinical trial, known as VOLGA, involving 695 patients with muscle-invasive bladder cancer across 229 medical centers in 25 countries. All participants were unable to receive or refused standard cisplatin-based chemotherapy.
Patients were randomized into one of three study arms. The first cohort received durvalumab and enfortumab vedotin before radical cystectomy, followed by durvalumab alone after surgery. The second cohort received the same treatment with the addition of another immunotherapy drug, tremelimumab. The third cohort underwent surgery alone without the study drug combinations.
The researchers then evaluated how long patients lived without their cancer returning or progressing, as well as overall survival, treatment response, and side effects.
The researchers found that patients who received durvalumab and enfortumab vedotin had significantly better outcomes than those who underwent surgery alone.
At two years, 78.4% of patients receiving the two-drug combination were alive, compared with 69.4% of patients who underwent surgery alone. The treatment also helped patients remain free of cancer recurrence or progression for longer, with 63.5% of patients in the combination cohort experiencing no cancer-related events at two years, compared with 45.1% in the surgery-alone cohort.
The combination was also particularly effective at eliminating detectable cancer before surgery. Researchers found that 45.1% of patients receiving the two-drug treatment had no detectable cancer remaining in the tissue examined after surgery, compared with just 9.6% of patients who underwent surgery alone.
The three-drug combination that included tremelimumab also significantly reduced the risk of cancer-related events or death compared with surgery alone but did not show a statistically significant improvement in overall survival at this stage of the study.
Severe side effects were more common among patients receiving the drug combinations. However, the researchers reported no unexpected safety problems with the two-drug treatment, and it did not appear to increase complications related to surgery.
One of the distinguishing features of the VOLGA trial is that patients received enfortumab vedotin only before surgery, rather than both before and after surgery as in other recently studied treatment approaches. Following radical cystectomy, patients continued with immunotherapy alone, potentially reducing the burden of additional treatment and treatment-related toxicity during recovery from a major operation that can significantly affect patients' quality of life.
"What makes this approach particularly important is that patients don't have to continue receiving the targeted cancer drug after surgery," Drakaki said, emphasizing the importance of reducing post-operative toxicity and improving quality-of-life metrics during recovery. "We are seeing meaningful survival benefits with immunotherapy alone after surgery, which could help reduce the treatment and financial burden for patients during an already challenging time."
Drakaki noted that longer follow-up is needed to determine whether the three-drug combination of enfortumab vedotin, durvalumab, and tremelimumab improves overall survival. In the meantime, the current findings support the combination of durvalumab and enfortumab vedotin as a potential new treatment option for patients with muscle-invasive bladder cancer who are unable or unwilling to receive standard cisplatin-based chemotherapy.
Funding: The study was funded by AstraZeneca.
Published in journal: New England Journal of Medicine
Title: Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
Authors: Thomas Powles, M.D., Enrique Grande, M.D., Giuseppe Simone, M.D., Alfonso Gómez de Liaño, M.D., Marco Maruzzo, M.D., Ph.D., Pedro Isaacsson Velho, M.D., Ph.D., Eiji Kikuchi, M.D., Ph.D., Toan Quang Vu, M.D., Lazar Popovic, M.D., Ph.D., Timuçin Çil, M.D., Gwenaelle Gravis, M.D., Robert Radkowski, M.D., Luis Raúl Novelo Hernández, M.D., Hernán Javier Cutuli, M.D., Aristotelis Bamias, M.D., Ph.D., Thomas Bauernhofer, M.D., Michel Pavic, M.D., Yoon Ji Choi, M.D., Ph.D., Chao-Hsiang Chang, M.D., Hiroshi Kitamura, M.D., Ph.D., Jonathan E. Rosenberg, M.D., Jacqui Rowbottom, M.Sc., Svetlana Ho, M.D., Ashok Gupta, M.D., Ph.D., Alexandra Drakaki, M.D., Ph.D., for the VOLGA Investigators
Source/Credit: University of California, Los Angeles / Health | Denise Heady
Edited by: Scientific Frontline
Reference Number: ongy110926_02
